Sichuan Haisco Pharmaceutical Co. Ltd. has developed pyrazinone derivatives acting as protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors. They are reported to be useful for the treatment of cancer.
Protein tyrosine kinase 7 (PTK7) is a pseudo tyrosine kinase overexpressed in many cancer types such as ovarian, triple-negative breast cancer (TNBC), non-small-cell lung cancer, small-cell lung cancer and bladder cancer, but limited expression in normal tissues.
Researchers from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Doma Biopharmaceutical (Suzhou) Co. Ltd. reported the discovery and preclinical data of DM-005, a novel fully human EGFR × MET bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.
A team of scientists at the University of Massachusetts Chan Medical School has discovered the putative cancer target UDP-glucuronate decarboxylase 1 (UXS1) in cancer cells expressing high levels of UDP-glucose 6-dehydrogenase (UGDH). UXS1 is a Golgi enzyme that appears downstream of UGDH and converts UDP-glucuronate (UDPGA) to UDP-xylose. The study also showed that UXS1 not only cleared away UDPGA but also limited its production through negative feedback on UGDH. They published their results on Oct. 25, 2023, in the online edition of Nature.
Debiopharm Research & Manufacturing SA has disclosed new antibody-drug conjugates consisting of monoclonal antibodies targeting CD37 covalently linked to a cytotoxic agent through a linker.
Work at Suzhou Genhouse Bio Co. Ltd. has led to the discovery of oxadiazole compounds acting as histone deacetylase 6 (HDAC6) inhibitors and thus reported to be potentially useful for the treatment of cancer, asthma, Alzheimer’s disease, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.
Humanwell Healthcare (Group) Co. Ltd. has identified new kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, psoriasis, atopic dermatitis, autoimmune diseases and inflammatory bowel disease.
Nerio Therapeutics Inc. has patented new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases.
Invios GmbH and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate Invios' immune-activating small molecule, INV-501, as a potential treatment for glioblastoma.
KLRG1 is expressed on a subset of T and NK cells, with KLRG1+CD8+ T cells having demonstrated strong antitumor cytotoxicity by releasing IFN-γ and TNF-α.
RSS
